Giant Axonal Neuropathy Market Size and Share Analysis, Growth Opportunities, Challenges, Key Companies, Treatment Algorithm, Emerging Pipeline Therapies, and Epidemiology Forecasted [Mark...
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: MarketWatch
Giant Axonal Neuropathy: An Overview Giant axonal neuropathy (GAN) is a rare inherited genetic disorder that severely affects the peripheral as well as the central nervous system. GAN is characterized by abnormally large and dysfunctional axons called giant axons. The onset of GAN ranges from early infancy to late childhood Treatment of Giant Axonal Neuropathy is symptomatic and supportive in nature and often encompasses multiple teams of medical professionals Services for visually and/or mobility impaired people may be of help to people with GAN. Giant Axonal Neuropathy Market Key Facts As per the Orphanet (2021), the prevalence of GAN is unknown, but to date, approximately 50 families have been reported. The frequency of this disease, however, is likely to be underestimated, due to patients with incomplete phenotypes and a high level of consanguinity among some populations. It occurs equally in both sexes. Laguna et al. (2020), in a multicenter observational retrospective
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.00 price target on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.MarketBeat
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
TSHA
Earnings
- 11/14/23 - Miss
TSHA
Sec Filings
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form ARS
- 4/18/24 - Form DEF
- TSHA's page on the SEC website